Navigation Links
Researchers develop device that simulates gastro-intestinal tract
Date:3/31/2014

A breakthrough in drug testing developed by a University of Huddersfield lecturer could lead to cheaper, more effective medicines. Dr Hamid Merchant is a member of the team that has created a device which accurately simulates the gastro-intestinal tract and how it absorbs medication. This means that the cost of clinical trials could be greatly reduced, with savings passed on to customers.

Dr Merchant has joined the University as a Senior Lecturer in Pharmaceutics. Previously a postdoctoral fellow at University College London (UCL), he has extensive research experience, with a speciality in drug delivery and formulations. He has published regularly in peer-reviewed journals and made presentations to prestigious bodies that include the American Association of Pharmaceutical Scientists, to whom he has described his work in developing the apparatus for testing the solubility of medicines in their annual meeting and exposition in November 2013 at St Antonio (Links to abstracts... AAPS 2013-R6065, AAPS 2013-T3050, AAPS 2013-W5338, AAPS 2013-T3119, AAPS 2013-R6310).

The device is the subject of a patent application with potential commercial partners already expressing interest and a working prototype has been constructed at UCL. It has already been used, under contract, by drug companies in order to test new products. Dr Merchant now aims to establish a second prototype at the University of Huddersfield.

Dr Merchant explained that the cycle for developing and delivering a new drug involves pre-clinical tests on animals. If these are deemed safe and satisfactory, clinical trials on humans can then begin. But differences between animal and human gastrointestinal tracts mean that the pre-clinical tests do not always provide sufficiently reliable information about drug absorption from differing formulations. This has to be investigated at considerable expense during the clinical trial phase.

Therefore, Dr Merchant and his colleagues developed a laboratory device that simulates the human gut and its differing pH gradients, which play a decisive role in determining the manner, in which orally-administered medications are dissolved and then absorbed. It is now possible to fairly discriminate the formulations of a new drug and identify potential candidates for further development that are likely to be successful during clinical trials.

"By minimising human trials we would reduce the cost of development, which is then charged to patients when the drug comes to the market if the development costs are lower, then we can make new drugs more affordable," said Dr Merchant, who has research experience in industry as well as academia.

The testing device, co-developed by Dr Merchant, includes a chamber for holding a solvent medium plus a pH probe and a control unit. This monitors changes in the pH of the solvent medium in order to test the performance of a drug carrier at different levels of acidity or alkalinity, mimicking the conditions of the gastrointestinal tract. The device is particularly suitable for testing and developing dosage forms for oral delivery of drugs and can also simulate the variability between individuals.


'/>"/>

Contact: Nicola Werritt
nicola.werritt@hud.ac.uk
01-484-473-315
University of Huddersfield
Source:Eurekalert  

Related medicine news :

1. UNC researchers show cancer chemotherapy accelerates molecular aging
2. NUS researchers developed worlds first fluorescent sensor to detect date rape drug
3. Cancer researchers find key protein link
4. Researchers: Biomarkers predict effectiveness of radiation treatments for cancer
5. Researchers issue state-of-the-state on genetic-based testing and treatment for breast cancer
6. Researchers identify impaired new learning in persons with Parkinsons disease
7. Researchers identify potential new therapeutic target for controlling high blood sugar
8. Ottawa researchers find new pathway connected to type 2 diabetes
9. Shoulder revision repair surgery not as successful 2 years later, say researchers
10. Researchers find significant increase in painkillers prescribed to US adults in the ER
11. Dartmouth researchers develop new approach to chronic lymphocytic leukemia treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers develop device that simulates gastro-intestinal tract
(Date:1/24/2017)... New York (PRWEB) , ... January 24, 2017 , ... ... Brazilian butt lifts is on the rise. According to the American Society of ... since 2000. On average, these procedures are performed every 30 minutes of every day. ...
(Date:1/24/2017)... ... 24, 2017 , ... PeroxyChem Food and Beverage Safety announced ... at the International Production and Processing Expo (IPPE) in Atlanta, Georgia from Jan. ... that is used in poultry processing facilities to provide constant, real-time data that ...
(Date:1/24/2017)... ... January 24, 2017 , ... Twelve startups ... of the 2017 Cupid's Cup Entrepreneurship Competition. Chaired by Under Armour Founder and ... The entrepreneurs will showcase their businesses on February 6, 2017, at Under Armour’s ...
(Date:1/24/2017)... ... ... Bellus Medical, a leader in medical aesthetics, today announced that Marek Dobke, M.D., ... will provide physician oversight for in-house clinical studies and hands-on device training, among other ... Professor of Surgery at UC San Diego Health and is a board certified plastic ...
(Date:1/24/2017)... Boston, MA (PRWEB) , ... January 24, 2017 ... ... What They Really Need to Thrive , Well-meaning studies such as the Fordham ... and schools can better serve top students, such as including gifted or high-achieving ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... , Jan. 24, 2017   Intrexon Corporation ... and industrialization of biology to improve the quality of life ... entered into a definitive agreement to acquire GenVec, Inc ... pioneer in the development of AdenoVerse™ gene delivery technology.  ... expertise in adenoviral vectors and cGMP drug product manufacturing to ...
(Date:1/24/2017)... 24, 2017   Keneric Healthcare , a ... effective patient care products, today announced their partnership ... the reach of both companies by leveraging their ... Angelini Pharma Inc . ... include Keneric Healthcare,s RTD™ Wound Dressing (antibacterial/antifungal).  RTD™ ...
(Date:1/24/2017)... 2017 Stock-Callers.com today has issued research ... ZTS ), Mallinckrodt PLC (NYSE: MNK ), ... Inc. (NYSE: DPLO ). According to pharmaceutical manufacturer ... 2017 for the Generic Drugs industry, including a possible reduction ... current growth, and a speedier FDA approval process that could ...
Breaking Medicine Technology: